In:
Diabetic Medicine, Wiley, Vol. 32, No. 11 ( 2015-11), p. 1479-1483
Kurzfassung:
Data on protective biomarkers for diabetic sensorimotor polyneuropathy are very scarce. Omentin is an adipokine with anti‐inflammatory, insulin‐sensitizing and cardioprotective properties. The present study found that high serum levels of omentin are also associated with a lower odds of polyneuropathy in people with Type 2 diabetes from the population‐based KORA F4 study. This inverse association was not explained by established risk factors and was partly independent of subclinical inflammation. Further studies should investigate whether omentin may represent a predictor of polyneuropathy and whether this protein may be of therapeutic use in people with diabetes and polyneuropathy.
Materialart:
Online-Ressource
ISSN:
0742-3071
,
1464-5491
DOI:
10.1111/dme.2015.32.issue-11
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2015
ZDB Id:
2019647-7